UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2015
OXiGENE, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
0-21990 |
13-3679168 |
||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
701 Gateway Boulevard, Suite 210, South San Francisco, CA |
94080 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (650) 635-7000
________________________________________________________________________________
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
||
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 2.02. Results of Operations and Financial Condition.
On April 30, 2015 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated April 30, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OXiGENE, Inc. |
||
| Date: April 30, 2015 | By: | /s/ DAVID J. CHAPLIN David J. Chaplin Chief Executive Officer |
EXHIBIT 99.1
SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter ended March 31, 2015.
"We continue to make good progress toward achieving our goals for 2015, which are focused on advancing our pipeline of novel oncology therapeutics," said Dai Chaplin, Ph.D., OXiGENE's President and CEO. "Our clinical programs for fosbretabulin in gastrointestinal neuroendocrine tumors (GI-NETs) and for OXi4503 in acute myeloid leukemia are moving forward as planned. We anticipate receiving definitive regulatory feedback from our meeting with the FDA on the design and scope of a potential late-stage development program for fosbretabulin in ovarian cancer by end of the second quarter. With our strengthened cash balance, we believe we are well positioned to continue to create value with our clinical pipeline."
Summary of Financial Results
At March 31, 2015, OXiGENE had cash of $36 million, compared to $30 million at December 31, 2014. During the first quarter of 2015, the company raised gross proceeds of $10 million from a private offering of stock and warrants.
For the quarter ended March 31, 2015, OXiGENE reported a net loss of $2.8 million compared to a net loss of $2.6 million for the comparable period in 2014. The increase of $0.2 million in the net loss in the first quarter of 2015 as compared to the first quarter of 2014 was due primarily to increased research and development (R&D) expenses.
R&D expenses during the first quarter of 2015 were $1.7 million compared to $1.4 million in the first quarter of 2014. The increase was primarily associated with costs related to the GI-NET Phase 2 trial, including clinical research expenses and compensation costs, which were offset in part by a decrease in manufacturing costs.
General and administrative expenses during the first quarter of 2015 were $1.1 million compared to $1.2 million in the first quarter of 2014.
Common stock outstanding as of March 31, 2015 was 26,544,934 shares.
Conference Call Today
Members of OXiGENE's management team will host a webcast and conference call today, April 30, 2015, at 4:30 p.m. EDT (1:30 p.m. PDT) to provide a first quarter 2015 financial and business update.
To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors & Media" tab, select the link to "Events and Presentations." OXiGENE's earnings conference call can also be heard live by dialing (888) 841-3431 in the United States and Canada, or +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call. The conference ID is 32409932.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
| OXiGENE, Inc. | ||
| Balance Sheet Data | ||
| (Unaudited) | ||
| March 31, 2015 | December 31, 2014 | |
| (All amounts in thousands) | ||
| Assets | ||
| Cash | $ 35,735 | $ 30,031 |
| Prepaid expenses | 755 | 318 |
| Other assets | 65 | 74 |
| Total assets | $ 36,555 | $ 30,423 |
| Liabilities and stockholders' equity | ||
| Accounts payable and accrued liabilities | $ 1,029 | $ 1,419 |
| Total stockholders' equity | 35,526 | 29,004 |
| Total liabilities and stockholders' equity | $ 36,555 | $ 30,423 |
| OXiGENE, Inc. | ||
| Statement of Operations Data | ||
| (Unaudited) | Three months ended March 31, | |
| 2015 | 2014 | |
| (All amounts in thousands, except per share data) | ||
| Operating Expenses: | ||
| Research and development | $ 1,669 | $ 1,387 |
| General and administrative | 1,108 | 1,241 |
| Total operating expenses | 2,777 | 2,628 |
| Loss from Operations | (2,777) | (2,628) |
| Investment income | 3 | 1 |
| Other (expense) income, net | 2 | (3) |
| Net loss and comprehensive loss | $ (2,772) | $ (2,630) |
| Basic and diluted net loss per common share attributable to common stock | $ (0.13) | $ (0.29) |
| Weighted-average number of common shares outstanding | 21,095 | 9,054 |
CONTACT: Investor and Media Contact:
ir@oxigene.com
650-635-7000